查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829174

動物用藥品原料藥（依動物類型、產品類型、化合物類型、給藥途徑和來源）－2025-2032 年全球預測

Animal Health Active Pharmaceutical Ingredients Market by Animal Type, Product Type, Compound Type, Route Of Administration, Source - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物用藥品原料藥市場將成長至 360.8 億美元，複合年成長率為 8.47%。

主要市場統計數據
基準年2024年 188.2億美元
預計2025年 203.9億美元
預測年份：2032年 360.8億美元
複合年成長率（%） 8.47%

動物用藥品原料藥領域的綜合框架強調了科學創新、監管現實和供應鏈複雜性，以形成戰略選擇

動物用藥品的原料藥藥物成分 (API) 處於科學創新、監管監督和複雜的全球供應鏈的交匯點。本介紹概述了再形成該行業的關鍵力量：對高價值生技藥品和多肽的需求不斷成長、對抗菌藥物管理的審查日益嚴格、給藥途徑偏好的不斷演變，以及對採購永續性和可追溯性的日益重視。這些動態與原料供應和物流的持續壓力相伴而生，要求更細緻的產品開發和採購方法。

加速的技術創新正在推動行業化合物類型和遞送系統的多樣化。生物製藥拓展了治療的可能性，但需要在生產能力和低溫運輸物流進行大量投資。同時，小分子對於許多關鍵適應症仍然至關重要，而胜肽則提供了一條將特異性與改進的生產過程相結合的中間路徑。法律規範不斷適應這些變化，強調品質源自於設計、藥物安全檢測，並明確要求提供支持目標物種安全性的數據。因此，組織必須在開發早期就將其科學策略與合規藍圖結合，以避免下游延遲。

供應鏈考量同樣是策略規劃的核心。原料藥的採購狀況——無論是發酵衍生、天然萃取物或合成——都會影響原料短缺、地緣政治事件和關稅變化所帶來的風險暴露。同時，給藥途徑的創新也會影響製劑的複雜性和生產足跡。吸入、口服、腸外和局部給藥各自反映不同的技術和商業性權衡。總而言之，這些主題為製造商、受託製造廠商、經銷商以及為下一波產品推出做準備的動物用藥品公司帶來了機會和風險。

分析重塑動物用藥品原料藥動態和製造方法的科學、運作和商業性融合力量。

動物用藥品原料藥領域正在經歷一系列變革時期正在改變競爭邊界和投資重點。首先，治療重點正轉向針對特定物種的標靶介入。生技藥品和多肽正在將治療範圍擴大到伴侶動物和高價值牲畜，而抗生素管理計畫正在推動配方改進和非抗生素替代品的開發。這種科學轉變需要新的製造能力、增強的低溫運輸物流以及研發和製造團隊之間更緊密的合作。

其次，為了應對持續的供應鏈中斷和不斷變化的貿易政策，市場參與企業正在重新評估其採購和製造足跡。這種重新調整體現在更注重區域供應鏈的彈性，更多地利用契約製造來靈活調整生產能力，以及對關鍵中間體進行策略性儲備。同時，永續性正從合規性考量轉變為競爭優勢。企業正在投資更綠色的化學製程、減少溶劑使用和廢棄物最小化策略，以減少對環境的影響並降低監管風險。

第三，數位化和數據主導的品質體係正在重塑整個研發和製造流程的營運效率。企業擴大採用製程分析技術、預測性維護和數位化批次記錄，以加快研發週期並增強可追溯性。監管機構也青睞能夠證明品質一致性的數位證據，從而形成良性循環，提高資料保真度可以減少檢查摩擦並加快核准。最後，我們看到各種合作模式層出不窮——從與學術中心的策略聯盟到跨產業聯盟——各組織都在尋求共用擔風險、挖掘專業技能，並加速將新型療法轉化為商業產品。這些轉變共同塑造了一個更模組化、更具彈性、更創新驅動的產業架構。

檢驗最近的關稅措施將如何顯著改變動物用藥品原料藥鏈中的採購經濟、供應商選擇和合規負擔

近期的關稅措施和貿易政策調整，增加了動物用藥品生物製藥原料藥採購、生產和分銷相關人員的複雜性。關稅不僅透過對成品原料藥和中間體徵收直接進口關稅來影響成本結構，還透過改變生物製劑和多肽藥物生產所需的原料、專用試劑和資本設備的採購成本來影響成本結構。為此，企業正在審查供應商契約，評估近岸外包方案，並重新評估總到岸成本模型，以保持利潤率和供應的連續性。

關稅不僅影響成本，還會推動整個價值鏈的行為改變。製造商可能會優先考慮國內或區域供應商的關鍵投入，從而可能加速對本地產能或委託製造夥伴關係關係的投資。相反，一些公司可能會選擇承擔額外的關稅，以維持與提供卓越品質或計劃能力的可信賴供應商的關係。對於監管團隊而言，關稅驅動的供應商變更通常需要補充檢驗工作和文件更新，以保持跨司法管轄區的合規性，從而增加專案時間表和管理負擔。

從策略上講，最具韌性的公司正在採用多層次的方法來應對關稅風險，將多元化採購、包含明確升級條款的長期供應合約以及庫存最佳化相結合，以緩衝短期衝擊。對供應商網路進行情境規劃和壓力測試可以揭示其脆弱性，並指導採取積極的緩解措施，例如對關鍵中間體進行雙重採購以及投資替代合成路線。此外，投資於供應鏈透明度和關稅影響分析的組織能夠更好地向商業夥伴和監管機構傳達價格調整和風險緩解策略，使他們在政策不確定性的情況下也能保持信任和市場進入。

將動物種類、治療類別、化合物類別、給藥途徑和原產國與開發和供應鏈要求聯繫起來的詳細細分分析

細分洞察揭示了科學創新、監管重點和商業性需求的交匯，從而在動物用藥品原料藥領域創造了差異化的機會。根據動物種類，水產養殖、伴侶動物、牲畜和家禽的市場需求促進因素和產品開發重點有顯著差異。伴侶動物通常引領尖端生技藥品的應用，而水產養殖則需要能夠耐受水生環境的製劑。按產品類型分類，治療產品組合涵蓋抗發炎藥物、抗生素、抗寄生蟲藥、荷爾蒙和疫苗，每個類別都面臨不同的製造和監管挑戰。疫苗和抗寄生蟲藥物通常需要強大的低溫運輸和穩定性策略，而小分子抗生素則強調經濟高效的合成路線和管理方案。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 長效注射藥物擴大被採用來改善牲畜疾病管理
  • 加強法規以減少動物糞便和周圍生態系統中的獸用 AP 殘留
  • 增加對新型獸醫免疫療法和疫苗重組蛋白 API 的投資
  • 動物用藥品公司與契約製造製造商建立策略聯盟以擴大 API 生產能力
  • 連續流合成技術在經濟高效、高純度獸藥 API 生產的進展
  • 獸藥原料藥採購中永續植物來源萃取方法的新興趨勢
  • 擴大拉丁美洲動物用藥品原料藥(API) 生產設施，以滿足該地區日益成長的蛋白質需求
  • 實施數位雙胞胎技術最佳化獸藥API程式參數並減少批次錯誤

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章動物用藥品原料藥（依動物類型）

  • 水產養殖
  • 伴侶動物
  • 家畜
  • 家禽

第9章動物用藥品原料藥（依產品類型）

  • 抗發炎藥物
  • 抗生素
  • 抗寄生蟲藥
  • 荷爾蒙
  • 疫苗

第 10 章動物用藥品原料藥（依化合物類型）

  • 生物製藥
  • 胜肽
  • 小分子

第11章動物用藥品原料藥依管理途徑

  • 吸入
    • 氣霧劑
    • 乾粉
    • 噴霧器
  • 口服
    • Bolus
    • 顆粒
    • 粉末
    • 藥片
  • 腸外
    • 肌肉注射
    • 靜脈
    • 皮下
  • 外用
    • 皮膚科
    • 眼科
    • 耳科

第12章動物用藥品原料藥市場（依來源）

  • 發酵衍生
  • 天然萃取物
  • 合成

第13章動物用藥品原料藥（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章動物用藥品原料藥：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章動物用藥品原料藥（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Virbac SA
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Dechra Pharmaceuticals PLC
    • Norbrook Laboratories Limited
Product Code: MRR-430D3EB72270

The Animal Health Active Pharmaceutical Ingredients Market is projected to grow by USD 36.08 billion at a CAGR of 8.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.82 billion
Estimated Year [2025] USD 20.39 billion
Forecast Year [2032] USD 36.08 billion
CAGR (%) 8.47%

Comprehensive framing of the animal health API arena emphasizing scientific innovation, regulatory realities, and supply chain complexity shaping strategic choices

The active pharmaceutical ingredients (APIs) that underpin animal health therapeutics are at the intersection of scientific innovation, regulatory oversight, and complex global supply chains. This introduction sets the stage by outlining the principal drivers reshaping the sector: rising demand for higher-value biologics and peptides, heightened scrutiny around antimicrobial stewardship, evolving route-of-administration preferences, and the increasing emphasis on sustainability and traceability in sourcing. These dynamics are occurring alongside persistent pressures on raw material availability and logistics, which together require a more nuanced approach to product development and procurement.

As innovation accelerates, the industry is witnessing a diversification of compound types and delivery systems. Biologic APIs are expanding therapeutic possibilities but also demand significant investments in manufacturing capability and cold-chain logistics. At the same time, small molecules remain essential for many core indications, and peptides offer a middle path that combines specificity with manufacturing improvements. Regulatory frameworks continue to adapt to these shifts, emphasizing quality-by-design, pharmacovigilance, and explicit requirements for data supporting safety in target species. Consequently, organizations must align scientific strategy with compliance roadmaps early in development to avoid downstream delays.

Supply chain considerations are equally central to strategic planning. The sourcing profile of APIs-whether fermentation derived, natural extracted, or synthetic-affects risk exposure to raw material shortages, geopolitical events, and tariff changes. In parallel, route-of-administration innovation influences formulation complexity and manufacturing footprints; inhalation, oral, parenteral, and topical modalities each present distinct technical and commercial trade-offs. Taken together, these themes create both opportunities and risks for manufacturers, contract development and manufacturing organizations, distributors, and veterinary pharmaceutical companies that are preparing for the next wave of product introductions.

Analysis of converging scientific, operational, and commercial forces that are remapping competitive dynamics and manufacturing approaches in animal health APIs

The animal health API landscape is undergoing a series of transformative shifts that are altering competitive boundaries and investment priorities. First, the therapeutic focus is gravitating toward targeted and species-specific interventions: biologics and peptides are expanding therapeutic reach for companion animals and high-value livestock applications, while antibiotic stewardship programs are driving reformulation and the development of non-antimicrobial alternatives. These scientific shifts necessitate new manufacturing capabilities, stronger cold-chain logistics, and closer collaboration between R&D and manufacturing teams.

Second, market participants are reassessing sourcing and manufacturing footprints in response to persistent supply chain disruptions and changing trade policies. This recalibration manifests as greater interest in regional supply network resilience, expanded use of contract manufacturing to flex capacity, and strategic stockpiling for critical intermediates. Simultaneously, sustainability has moved from a compliance checkbox to a competitive differentiator; companies are investing in greener chemistries, reduced solvent use, and waste minimization strategies that lower environmental impact while mitigating regulatory risk.

Third, digitalization and data-driven quality systems are reshaping operational effectiveness across development and manufacture. Companies increasingly deploy process analytical technology, predictive maintenance, and digital batch records to accelerate development cycles and enhance traceability. Regulatory authorities are also receptive to digital evidence demonstrating consistent quality, which creates a virtuous cycle: improved data fidelity reduces inspection friction and supports accelerated approvals. Finally, collaborative models-ranging from strategic alliances with academic centers to cross-industry consortia-are proliferating as organizations seek to share risk, access niche expertise, and accelerate the translation of novel modalities into commercial products. Collectively, these shifts are driving a more modular, resilient, and innovation-oriented industry architecture.

Examination of how recent tariff measures materially alter sourcing economics, supplier selection, and compliance burdens across the animal health API value chain

Recent tariff actions and trade policy adjustments have introduced an additional layer of complexity for actors engaged in the procurement, manufacture, and distribution of animal health APIs. Tariffs influence cost structures not only through direct import duties on finished APIs and intermediates but also by altering the economics of raw material sourcing, specialized reagents, and capital equipment required for biologic and peptide production. In response, organizations are revisiting supplier agreements, assessing nearshoring options, and reevaluating total landed cost models to preserve margins and continuity of supply.

Beyond cost implications, tariffs create behavioral shifts across the value chain. Manufacturers may prioritize domestic or regional suppliers for critical inputs, which can accelerate investment in local capacity and contract manufacturing partnerships. Conversely, some firms will choose to absorb additional duties to maintain relationships with trusted suppliers that offer superior quality or unique capabilities. For regulatory affairs teams, tariff-driven supplier changes often necessitate supplemental validation work and documentation updates to maintain compliance across jurisdictions, thereby increasing project timelines and administrative burden.

Strategically, the most resilient organizations adopt a layered approach to tariff exposure: they combine diversified sourcing, longer-term supply agreements with clear escalation clauses, and inventory optimization to smooth short-term shocks. Scenario planning and stress-testing of supplier networks reveal vulnerabilities and guide proactive mitigation measures, such as dual sourcing and investment in alternative synthesis routes for key intermediates. Moreover, organizations that invest in supply chain transparency and tariff impact analytics are better positioned to communicate price adjustments and risk mitigation strategies to commercial partners and regulators, preserving trust and market access despite policy uncertainty.

In-depth segmentation analysis linking animal type, therapeutic category, compound class, administration routes, and source origins to development and supply chain imperatives

Segmentation insights reveal where scientific innovation, regulatory focus, and commercial demand intersect to create differentiated opportunities across the animal health API landscape. Based on animal type, the market's demand drivers and product development priorities diverge significantly between aquaculture, companion animal, livestock, and poultry, with companion animals often leading adoption of cutting-edge biologics and aquaculture requiring formulations tolerant of aquatic environments. Based on product type, the therapeutic portfolio spans anti-inflammatories, antibiotics, antiparasitics, hormones, and vaccines, and each category presents distinct manufacturing and regulatory challenges; vaccines and antiparasitics typically demand robust cold-chain and stability strategies, whereas small-molecule antibiotics emphasize cost-effective synthetic routes and stewardship programs.

Based on compound type, biologics, peptides, and small molecules create three clear manufacturing pathways: biologics require cell-culture expertise and stringent aseptic environments; peptides benefit from advances in solid-phase synthesis and purification technologies; and small molecules continue to leverage mature chemical synthesis networks that prioritize yield and impurity control. Based on route of administration, inhalation, oral, parenteral, and topical routes impose different formulation constraints and delivery system investments. The inhalation modality further subdivides into aerosol, dry powder, and nebulization formats each with unique device and characterization demands, while the oral route includes bolus, granules, powder, and tablet formats that influence animal dosing behavior and palatability considerations. Parenteral routes-intramuscular, intravenous, and subcutaneous-demand sterility assurance and compatibility testing, and topical applications-dermatological, ophthalmic, and otic-require focused local-tolerability and stability studies.

Finally, based on source, fermentation derived, natural extracted, and synthetic origins affect supplier ecosystems and risk profiles: fermentation derived APIs can tie manufacturers to biotech supply chains and fermentation capacity constraints, natural extracts present variability and sustainability questions, and synthetic APIs lean on chemical precursor availability and process innovation. Understanding these segmentation layers in aggregate enables targeted investment, regulatory planning, and commercialization strategies that are appropriate for specific therapeutic targets and end-user contexts.

Strategic regional assessment that contrasts regulatory sophistication, manufacturing capabilities, and commercialization dynamics across global regions to inform localization

Regional dynamics play a pivotal role in shaping sourcing strategies, regulatory expectations, and commercial adoption across the animal health API sector. The Americas present a mature regulatory environment and advanced manufacturing capabilities, with strong demand for high-value therapeutics in companion and specialty livestock applications. Market participants in this region increasingly focus on biologics and peptide innovation, supported by robust clinical trial infrastructures and established cold-chain logistics, while also navigating supply chain security and tariff-driven cost considerations.

Europe, Middle East & Africa combines diverse regulatory regimes and market maturities, ranging from highly harmonized European standards to emerging regulatory frameworks in parts of the Middle East and Africa. This heterogeneity creates both challenges and opportunities: companies can leverage Europe's stringent quality expectations to validate premium products, while regionally tailored strategies are necessary to address affordability constraints and distribution complexities across varied geographies. Sustainability and antimicrobial stewardship are particularly prominent themes in this region, influencing both regulation and purchasing decisions.

Asia-Pacific is characterized by rapid demand growth, developing manufacturing capabilities, and a complex patchwork of regulatory pathways. The region is a critical node for chemical and biologic production, and many organizations rely on Asia-Pacific suppliers for key intermediates and API manufacturing. At the same time, rising domestic R&D investments and increasing regulatory sophistication are creating new centers of innovation and localized product development. Across all regions, companies that align manufacturing, regulatory, and commercial strategies to regional characteristics gain competitive advantage and reduce market-entry friction.

Evaluation of how corporate strategies, capability specialization, and collaborative models are reshaping competitive advantages and partnership patterns in the API ecosystem

Company-level dynamics are being reshaped by a combination of strategic investment, capability specialization, and collaborative linkages across the value chain. Leading firms and specialized contract development and manufacturing organizations are differentiating through focused capability stacks-such as biologics process development, peptide synthesis scale-up, or complex inhalation device integration-to serve niche clinical and commercial needs. These capability clusters create higher barriers to entry for commodity players while opening partnership opportunities for firms that lack in-house expertise.

At the same time, mergers, strategic alliances, and technology licensing are common mechanisms for companies to accelerate capability acquisition and market entry without the full burden of capital investment. Such arrangements frequently involve cross-border collaboration and create implications for intellectual property management, regulatory filings, and cross-jurisdictional quality systems. Talent and technical know-how remain limiting factors in advanced modalities; companies that invest in workforce development and knowledge transfer programs secure a reproducible advantage in complex API production.

Finally, firms that proactively embed sustainability, traceability, and digital quality systems into their operations increase their appeal to large purchasers and regulatory stakeholders. Demonstrable commitments to greener chemistries, lower carbon footprints, and transparent sourcing strengthen commercial positioning and can accelerate approvals in markets prioritizing environmental stewardship. Collectively, these company-level moves determine who can deliver high-complexity APIs reliably and cost-effectively into an increasingly demanding market.

Actionable playbook for executives to enhance resilience, accelerate biologics and peptide capabilities, and optimize sourcing and regulatory engagement in animal health APIs

Industry leaders should pursue a pragmatic combination of strategic investments and operational adjustments to convert risk into opportunity. First, diversify supplier networks and build regional redundancy for critical intermediates and specialized reagents to reduce exposure to single points of failure and tariff volatility. Investing in dual sourcing and nearshoring for priority inputs supports continuity while enabling faster regulatory response when supplier changes are required. Second, allocate capital toward biologics and peptide manufacturing capabilities where scientific and commercial signals indicate durable demand; paired with strategic partnerships, this reduces time-to-market and leverages external expertise without overextending internal resources.

Third, prioritize route-of-administration innovation that aligns with end-user preferences and administration feasibility; for companion animals, palatability and easy-to-administer formats are often decisive, whereas for livestock and poultry, dosing efficiency and cost per treatment dominate decisions. Fourth, enhance regulatory engagement early and often: share development plans with regulatory bodies, pursue parallel consultations across jurisdictions when feasible, and standardize documentation to reduce approval timelines and inspection risk. Fifth, embed sustainability in procurement and process design through greener chemistry choices, waste reduction programs, and transparent sourcing protocols that can be evidenced to buyers and regulators.

Finally, operationalize data and digital solutions to improve traceability, predictive maintenance, and quality assurance. Implementing process analytical technologies and robust batch record systems reduces variability and supports faster scale-up. Scenario planning and tariff-impact modeling should be integrated into commercial and procurement decision processes so that price adjustments and sourcing shifts can be made proactively and communicated clearly to stakeholders. Taken together, these steps help create a resilient, innovation-ready organization capable of navigating emerging policy and market challenges.

Transparent research methodology combining primary interviews, secondary literature, and triangulated evidence to produce robust, actionable industry insights

The research underpinning this analysis combines primary qualitative insights with comprehensive secondary data synthesis to ensure robustness and relevance. Primary inputs include structured interviews with industry stakeholders such as formulation scientists, manufacturing leaders, procurement professionals, veterinary clinical experts, and regulatory affairs specialists. These conversations provided frontline perspectives on supply chain constraints, technological adoption, and unmet therapeutic needs across different animal types and administration routes. Where possible, cross-validation with multiple stakeholder groups was used to reconcile differing views and identify persistent patterns.

Secondary research encompassed authoritative scientific literature, regulatory guidance documents, patent filings, and public disclosures of manufacturing investments and partnerships. Information from trade publications and conference proceedings supplemented these sources to capture recent product launches, technology demonstrations, and collaborative announcements. Data triangulation ensured that conclusions were not reliant on any single source and allowed for the identification of convergent trends across independent inputs.

Methodological rigor included clear inclusion criteria for sources, transparent documentation of interview protocols, and quality checks on interpretive analysis. Limitations are acknowledged: rapidly evolving policies and commercial arrangements may change the competitive landscape between updates, and access constraints limit the granularity of some proprietary supply agreements. To mitigate these factors, the methodology emphasizes scenario-based insights and identifies leading indicators that stakeholders can monitor to update their strategic assessments in real time.

Concise synthesis of the strategic imperatives and operational priorities that will determine success in the evolving animal health API market

The cumulative picture is one of an industry in transition, where scientific advancements, regulatory evolution, and supply chain realities intersect to redefine strategic priorities. Biologics and peptides are reshaping therapeutic possibilities, whereas small molecules retain a central role in core indications. Route-of-administration choices and source origins materially influence manufacturing complexity, regulatory requirements, and commercial uptake, and they must be considered as integral elements of product strategy rather than afterthoughts.

Regional dynamics and tariff environments further complicate planning, making supply chain transparency and diversified sourcing essential components of resilience. Companies that invest in specialized capabilities, embrace collaborative models for capacity and knowledge sharing, and embed sustainability and digital quality systems into their operations will be best positioned to capture the upside of innovation while controlling downside risk. Ultimately, a disciplined, multidimensional approach that links R&D, manufacturing, procurement, regulatory, and commercial teams yields the strongest foundation for long-term success in the animal health API sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of long-acting injectable API formulations to improve livestock disease management
  • 5.2. Rising regulatory focus on reducing veterinary API residues in animal waste and surrounding ecosystems
  • 5.3. Increased investments in recombinant protein APIs for novel veterinary immunotherapies and vaccines
  • 5.4. Strategic collaborations between animal health companies and contract manufacturers to scale API production capacity
  • 5.5. Advancements in continuous flow synthesis for cost-effective and high-purity veterinary API manufacturing
  • 5.6. Emerging trend of sustainable plant-based extraction methods for veterinary API raw material sourcing
  • 5.7. Expansion of animal health API production facilities in Latin America to meet growing regional protein demand
  • 5.8. Implementation of digital twin technology to optimize veterinary API process parameters and reduce batch failures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Health Active Pharmaceutical Ingredients Market, by Animal Type

  • 8.1. Aquaculture
  • 8.2. Companion Animal
  • 8.3. Livestock
  • 8.4. Poultry

9. Animal Health Active Pharmaceutical Ingredients Market, by Product Type

  • 9.1. Anti Inflammatories
  • 9.2. Antibiotics
  • 9.3. Antiparasitics
  • 9.4. Hormones
  • 9.5. Vaccines

10. Animal Health Active Pharmaceutical Ingredients Market, by Compound Type

  • 10.1. Biologic
  • 10.2. Peptide
  • 10.3. Small Molecule

11. Animal Health Active Pharmaceutical Ingredients Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Aerosol
    • 11.1.2. Dry Powder
    • 11.1.3. Nebulization
  • 11.2. Oral
    • 11.2.1. Bolus
    • 11.2.2. Granules
    • 11.2.3. Powder
    • 11.2.4. Tablet
  • 11.3. Parenteral
    • 11.3.1. Intramuscular
    • 11.3.2. Intravenous
    • 11.3.3. Subcutaneous
  • 11.4. Topical
    • 11.4.1. Dermatological
    • 11.4.2. Ophthalmic
    • 11.4.3. Otic

12. Animal Health Active Pharmaceutical Ingredients Market, by Source

  • 12.1. Fermentation Derived
  • 12.2. Natural Extracted
  • 12.3. Synthetic

13. Animal Health Active Pharmaceutical Ingredients Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Health Active Pharmaceutical Ingredients Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Health Active Pharmaceutical Ingredients Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Elanco Animal Health Incorporated
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Virbac SA
    • 16.3.6. Ceva Sante Animale S.A.
    • 16.3.7. Vetoquinol S.A.
    • 16.3.8. Phibro Animal Health Corporation
    • 16.3.9. Dechra Pharmaceuticals PLC
    • 16.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL